Last reviewed · How we verify
Rituximab and Lenalidomide — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Rituximab and Lenalidomide (Rituximab and Lenalidomide) — Arbeitsgemeinschaft medikamentoese Tumortherapie.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Rituximab and Lenalidomide TARGET | Rituximab and Lenalidomide | Arbeitsgemeinschaft medikamentoese Tumortherapie | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Rituximab and Lenalidomide CI watch — RSS
- Rituximab and Lenalidomide CI watch — Atom
- Rituximab and Lenalidomide CI watch — JSON
- Rituximab and Lenalidomide alone — RSS
Cite this brief
Drug Landscape (2026). Rituximab and Lenalidomide — Competitive Intelligence Brief. https://druglandscape.com/ci/rituximab-and-lenalidomide. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing